Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatectomy | 5 | 2025 | 58 | 1.820 |
Why?
|
| Pancreatic Neoplasms | 7 | 2025 | 540 | 1.480 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2020 | 2 | 0.840 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2021 | 1 | 0.760 |
Why?
|
| Gallbladder | 1 | 2021 | 8 | 0.760 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 474 | 0.720 |
Why?
|
| Gastrostomy | 1 | 2020 | 7 | 0.670 |
Why?
|
| Patient Readmission | 1 | 2021 | 103 | 0.660 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 29 | 0.660 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 40 | 0.640 |
Why?
|
| Patient Transfer | 1 | 2017 | 43 | 0.540 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 409 | 0.470 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 183 | 0.460 |
Why?
|
| Adenocarcinoma | 3 | 2022 | 298 | 0.440 |
Why?
|
| Pancreaticoduodenectomy | 3 | 2020 | 42 | 0.360 |
Why?
|
| Common Bile Duct Neoplasms | 2 | 2020 | 5 | 0.340 |
Why?
|
| Ampulla of Vater | 2 | 2020 | 6 | 0.340 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2025 | 138 | 0.340 |
Why?
|
| Pancreatic Fistula | 2 | 2021 | 14 | 0.330 |
Why?
|
| Humans | 18 | 2025 | 28095 | 0.320 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2025 | 113 | 0.310 |
Why?
|
| Liver Neoplasms | 2 | 2020 | 165 | 0.290 |
Why?
|
| Retrospective Studies | 7 | 2025 | 2546 | 0.280 |
Why?
|
| Prognosis | 4 | 2025 | 802 | 0.250 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 478 | 0.240 |
Why?
|
| Splenectomy | 1 | 2024 | 44 | 0.220 |
Why?
|
| Vaccines | 1 | 2024 | 34 | 0.210 |
Why?
|
| England | 1 | 2021 | 39 | 0.190 |
Why?
|
| Middle Aged | 7 | 2025 | 7138 | 0.180 |
Why?
|
| Exosomes | 1 | 2023 | 96 | 0.180 |
Why?
|
| Aged | 6 | 2025 | 5400 | 0.180 |
Why?
|
| Duodenal Neoplasms | 1 | 2020 | 6 | 0.170 |
Why?
|
| Carcinoid Tumor | 1 | 2020 | 3 | 0.170 |
Why?
|
| Receptors, Somatostatin | 1 | 2020 | 8 | 0.170 |
Why?
|
| Trauma Centers | 2 | 2018 | 118 | 0.170 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 33 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 48 | 0.170 |
Why?
|
| Intestine, Small | 1 | 2020 | 66 | 0.160 |
Why?
|
| Deoxycytidine | 1 | 2020 | 65 | 0.160 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 125 | 0.160 |
Why?
|
| Lymph Nodes | 1 | 2020 | 103 | 0.160 |
Why?
|
| Choledochal Cyst | 1 | 2019 | 5 | 0.160 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2019 | 19 | 0.160 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 99 | 0.160 |
Why?
|
| Patient Selection | 1 | 2020 | 148 | 0.160 |
Why?
|
| Leucovorin | 3 | 2025 | 19 | 0.150 |
Why?
|
| Fluorouracil | 3 | 2025 | 58 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2018 | 29 | 0.150 |
Why?
|
| Health Expenditures | 1 | 2018 | 30 | 0.150 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 9 | 0.150 |
Why?
|
| Medically Uninsured | 1 | 2018 | 31 | 0.150 |
Why?
|
| Laparoscopy | 1 | 2020 | 146 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 3 | 2025 | 73 | 0.150 |
Why?
|
| Male | 8 | 2025 | 13490 | 0.150 |
Why?
|
| Spinal Cord Injuries | 1 | 2018 | 56 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 131 | 0.150 |
Why?
|
| Risk Factors | 2 | 2021 | 2081 | 0.150 |
Why?
|
| Tobacco Smoking | 1 | 2018 | 38 | 0.150 |
Why?
|
| Length of Stay | 1 | 2018 | 229 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2020 | 1248 | 0.140 |
Why?
|
| Internship and Residency | 1 | 2020 | 239 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2021 | 611 | 0.130 |
Why?
|
| Female | 7 | 2025 | 15155 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 819 | 0.120 |
Why?
|
| Adult | 4 | 2025 | 7740 | 0.120 |
Why?
|
| Neoplasms | 1 | 2023 | 808 | 0.110 |
Why?
|
| Survival Rate | 2 | 2025 | 430 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2025 | 612 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 226 | 0.080 |
Why?
|
| Sex Factors | 2 | 2019 | 466 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 47 | 0.050 |
Why?
|
| Spleen | 1 | 2024 | 112 | 0.050 |
Why?
|
| Pancreas | 1 | 2024 | 61 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 2021 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2023 | 29 | 0.050 |
Why?
|
| Lysosomes | 1 | 2023 | 56 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2019 | 2378 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 68 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 385 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2020 | 12 | 0.040 |
Why?
|
| Nomograms | 1 | 2020 | 9 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 104 | 0.040 |
Why?
|
| Suture Techniques | 1 | 2020 | 29 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 100 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 54 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 190 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 194 | 0.040 |
Why?
|
| Gastroenterology | 1 | 2019 | 15 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 288 | 0.040 |
Why?
|
| Contrast Media | 1 | 2019 | 96 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2023 | 1319 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2018 | 31 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 37 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2020 | 229 | 0.040 |
Why?
|
| Linear Models | 1 | 2018 | 202 | 0.040 |
Why?
|
| Curriculum | 1 | 2020 | 291 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 243 | 0.040 |
Why?
|
| Prevalence | 1 | 2019 | 497 | 0.040 |
Why?
|
| Oklahoma | 1 | 2018 | 1007 | 0.030 |
Why?
|
| Young Adult | 1 | 2018 | 2733 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 3122 | 0.020 |
Why?
|